Joe Biden Suggests Novo Nordisk, Eli Lilly To Lower Prices For Its Popular Obesity Drugs
Portfolio Pulse from Vandana Singh
President Joe Biden and Sen. Bernie Sanders have urged pharmaceutical companies like Novo Nordisk and Eli Lilly to lower the prices of their popular obesity drugs. The U.S. government has implemented policies to cap drug costs and negotiate prices, but further legislative measures may be taken if companies do not comply. Both Novo Nordisk and Eli Lilly have seen stock declines following these announcements.
July 02, 2024 | 3:38 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Eli Lilly is being urged by the U.S. government to reduce the price of its diabetes and weight loss drug, Mounjaro. Legislative measures may be enforced if prices remain high.
Eli Lilly is facing pressure to lower the price of Mounjaro, which could affect its revenue. The potential for legislative action adds to the uncertainty.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100
NEGATIVE IMPACT
Novo Nordisk is under pressure from the U.S. government to lower the prices of its obesity drugs, Ozempic and Wegovy. Failure to comply may result in legislative action.
The U.S. government is pushing for lower drug prices, which could impact Novo Nordisk's revenue from its high-priced obesity drugs. The threat of legislative action adds further pressure.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100